BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bielsky M, Cook A, Wallington A, Exley A, Kauser S, Hay JL, Both L, Brown D. Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial. Drug Discovery Today 2020;25:1910-8. [DOI: 10.1016/j.drudis.2020.09.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Brownlee WJ, Wolf C, Hartung HP, Dingermann T, Anshasi N, Clark RA, Trojano M, Selmaj K, Uitdehaag BM, Tur C, Wuerfel J, Dallmann G, Witte J, Sintzel M, Bobrovnikova O, Cohen JA. Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations. Mult Scler 2022;:13524585221116269. [PMID: 36000489 DOI: 10.1177/13524585221116269] [Reference Citation Analysis]
2 Kurki P, Kang HN, Ekman N, Knezevic I, Weise M, Wolff-Holz E. Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. BioDrugs 2022. [PMID: 35596890 DOI: 10.1007/s40259-022-00533-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Schreiber S, Puig L, Gonçalves J, Mease PJ, Panaccione R, Emery P. Critical Appraisal and Future Outlook on Anti-Inflammatory Biosimilar Use in Chronic Immune-Mediated Inflammatory Diseases. Seminars in Arthritis and Rheumatism 2022. [DOI: 10.1016/j.semarthrit.2022.152023] [Reference Citation Analysis]
4 Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, Mueller M, Peyrin-Biroulet L. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? Drugs 2021;81:1859-79. [PMID: 34705255 DOI: 10.1007/s40265-021-01610-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kurki P, Barry S, Bourges I, Tsantili P, Wolff-Holz E. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. Drugs 2021;81:1881-96. [PMID: 34596876 DOI: 10.1007/s40265-021-01601-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
6 Webster CJ, George KL, Woollett GR. Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance. BioDrugs 2021;35:379-87. [PMID: 34143406 DOI: 10.1007/s40259-021-00488-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Rojas-Chavarro LF, de Mora F. Extrapolation: Experience gained from original biologics. Drug Discov Today 2021;26:2003-13. [PMID: 34022458 DOI: 10.1016/j.drudis.2021.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Díaz LP, Millán S, Chaban N, Campo AD, Spitzer E. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars. Future Oncol 2021;17:2529-44. [PMID: 33904318 DOI: 10.2217/fon-2020-0923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Prior S, Metcalfe C, Hufton SE, Wadhwa M, Schneider CK, Burns C. Maintaining 'standards' for biosimilar monoclonal antibodies. Nat Biotechnol 2021;39:276-80. [PMID: 33664522 DOI: 10.1038/s41587-021-00848-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
10 Wang H, Wu L, Wang C, Xu J, Yin H, Guo H, Zheng L, Shao H, Chen G. Biosimilar or Not: Physicochemical and Biological Characterization of MabThera and Its Two Biosimilar Candidates. ACS Pharmacol Transl Sci 2021;4:790-801. [PMID: 33860202 DOI: 10.1021/acsptsci.0c00225] [Reference Citation Analysis]
11 Alsamil AM, Giezen TJ, Egberts TC, Leufkens HG, Gardarsdottir H. Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. Pharmaceuticals (Basel) 2021;14:189. [PMID: 33669108 DOI: 10.3390/ph14030189] [Cited by in F6Publishing: 3] [Reference Citation Analysis]